Trial Profile
Double Blind, Placebo-Controlled Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0259 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs GLPG 0259 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 06 Aug 2009 Results were reported in a Galapagos NV media release
- 06 Aug 2009 Status changed from active, no longer recruiting to completed, according to a Galapagos NV media release.
- 04 Aug 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.